Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesHematology/OncologyHealthSpring Oncology Medication Coverage | OpenPa…
    Ask Trek AI about this page
    ModifiedHealthSpringPolicy RX502.061

    Oncology and Supportive Care Medications

    Customize your policy alerts

    Sign up for healthspring Policy RX502.061 alerts

    Get alerted when Policy RX502.061 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity and coding for oncology medications and related supportive care medications. Oncology drugs may be covered when administered according to FDA labeling for an oncologic indication or when supported by specified NCCN recommendations; the listed medication codes are illustrative and not all-inclusive.

    Policy Summary
    PayerHealthSpring
    PolicyOncology and Supportive Care Medications
    Policy CodePolicy RX502.061
    Change TypeTable 1 medication and code list updated
    Effective DateOctober 20, 2026
    Next Review DateN/A
    Key ActionReview the Medical Policy and the member’s benefit contract or Summary Plan Description when making coverage determinations.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    The oncology medication and code list in Table 1 was updated on October 20, 2026.

    The oncology medication and code list in Table 1 was previously updated on July 21, 2026.

    2Medical-necessity pathways
    1, 2A, 2BNCCN categories supporting coverage
    Not all-inclusiveMedication and code table scope
    NCCNKey clinical source
    RequiredBenefit document review

    Oncology Medication Medical Necessity

    Oncology Medication Medical Necessity

    Oncology medications may be considered medically necessary when either of the following criteria is met:

    Medical necessity pathways

    • FDA-approved oncologic use: The drug is approved and is administered in accordance with U.S. Food and Drug Administration (FDA) labeling for an oncologic indication.FDA labeling for an oncologic indication
    • NCCN-supported use: The drug has a category 1, 2A, or 2B recommendation in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology or its derivative information product, the NCCN Drugs & Biologics Compendium.NCCN category 1, 2A, or 2B recommendation

    Oncology and Supportive-Care Medication Codes

    Oncology medications and codes: A through Aucatzylmixed
    0537TIdecabtagene vicleucel; Abecma
    0538TIdecabtagene vicleucel; Abecma
    0539TIdecabtagene vicleucel; Abecma
    0540TIdecabtagene vicleucel; Abecma
    Q2055Paclitaxel protein-bound particles; Abraxane
    J9264Paclitaxel protein-bound particles; Abraxane
    J3262Tocilizumab; Actemra
    J9216Interferon gamma 1-b; Actimmune
    J9042Brentuximab vedotin; Adcetris
    J9000Doxorubicin HCL; Adriamycin PFS
    1–10 of 27
    1/3
    Oncology medications and codes: Avastin through Cyramzamixed
    J9035Bevacizumab; Avastin
    J9184Gemcitabine HCL; Avyxa
    J9186Etoposide; Avyxa
    Q5156Tocilizumab-anoh; Avtozma
    J9023Avelumab; Bavencio
    J9174Docetaxel; Beizray
    J9032Belinostat; Beleodaq
    J9036Bendamustine HCL; Belrapzo
    J9034Bendamustine HCL; Bendeka
    J9066Bendamustine HCL; bendamustine
    1–10 of 38
    1/4
    Oncology medications and codes: Dacogen through Gemzarmixed
    J0894Decitabine; Dacogen
    J9348Naxitamab-gqgk; Danyelza
    J9145Daratumumab; Darzalex
    J9144Daratumumab and hyaluronidase-fihj; Darzalex Faspro
    J9011Datopotamab deruxtecan-dlnk; Datroway
    J0893Decitabine; Decitabine
    J9232Docetaxel; Docetaxel
    Q2050Doxorubicin liposomal; Doxil
    J9130Dacarbazine; DTIC-Dome
    J9063Mirvetuximab soratansine; Elahere
    1–10 of 32
    1/4
    Oncology medications and codes: Hematology/oncology medications through Monjuvimixed
    J9179Eribulin; Halaven
    J9355Trastuzumab; Herceptin
    J9356Trastuzumab and hyaluronidase-oysk; Herceptin Hycleta
    Q5146Trastuzumab-pkrb; Herzuma
    Q5113Trastuzumab-pkrb; Herzuma
    J9351Topotecan; Hycamtin
    J9211Idarubicin HCL; Idamycin
    J9256Nipocalimab-aahu; Imaavy
    J9173Durvalumab; Imfinzi
    J9347Tremelimumab-actl; Imjudo
    1–10 of 51
    1/6
    Oncology and supportive-care medication codesHCPCS
    J9047Carfilzomib
    J9278Tbo-filgrastim / Carboplatin (Avyxa) listing
    J9285Tbo-filgrastim / Olaratumab listing
    J2820Tbo-filgrastim / Sargramostim listing
    J9065Tbo-filgrastim / Cladribine listing
    J9119Tbo-filgrastim / Cemiplimab-rwlc listing
    J3263Tbo-filgrastim / Toripalimab-tpzi listing
    C9399Unclassified drug or biological
    J3490Unclassified drugs
    J3590Unclassified biologics
    1–10 of 26
    1/3
    Oncology and supportive-care medication codesHCPCS
    Q5107Bevacizumab-awwb
    J9203Gemtuzumab ozogamicin
    J9390Vinorelbine tartrate
    J2506Pegfilgrastim
    96377Application of an on-body injector
    J1442Filgrastim
    J9268Pentostatin
    Q5110Filgrastim-aafi
    J9293Mitoxantrone HCL
    Q5148Filgrastim-txid
    1–10 of 25
    1/3
    Pemetrexed, oncology, and supportive-care medication codesHCPCS
    J9297Pemetrexed (Sandoz)
    J9322Pemetrexed (BluePoint)
    J9323Pemetrexed ditromethamine
    J9305Pemetrexed
    J9304Pemetrexed / Pemfexy
    J9314Pemetrexed (Teva)
    J9324Pemetrexed / Pemrydi RTU
    J9306Pertuzumab
    J9316Pertuzumab, trastuzumab, and hyaluronidase-zzxf
    J9060Cisplatin powder or solution
    1–10 of 30
    1/3
    Oncology and supportive-care medication codesHCPCS
    J9227Isatuximab-irfc
    J1930Lanreotide
    Q5127Pegfilgrastim-fpgk
    J2860Siltuximab
    J3055Talquetamab-tgvs
    0537TBrexucabtagene autoleucel / cellular therapy procedure listing
    0538TBrexucabtagene autoleucel / cellular therapy procedure listing
    0539TBrexucabtagene autoleucel / cellular therapy procedure listing
    0540TBrexucabtagene autoleucel / cellular therapy procedure listing
    Q2053Afamitresgene autoleucel
    1–10 of 37
    1/4
    Oncology and supportive-care medication codesHCPCS
    J9025Azacitidine
    J9370Vincristine sulfate
    J9056Bendamustine HCL
    J0644Leucovorin calcium (Avyxa)
    J1326Zolbetuximab-clzb
    J9153Daunorubicin and cytarabine
    Q5136Denosumab-bbdz
    Q5159Denosumab-dssb
    J0897Denosumab
    Q5167Denosumab-qbde
    1–10 of 24
    1/3

    Coverage Review and Use Requirements

    Documentation Required

    Review Policy and Member Benefit Documents

    Review the written Medical Policy together with the member’s benefit contract or Summary Plan Description (SPD) before making coverage or reimbursement determinations. Confirm defined coverage and non-coverage, benefit exclusions, and limitations such as dollar or duration caps.

    Note

    Non-Oncologic Use

    Some drugs may have non-oncologic indications. When a drug is used for a non-oncologic indication, refer to the applicable HCSC medical policy and/or the FDA prescribing information for guidance.

    Policy Background

    This policy addresses oncology medications and supportive-care medications used in cancer treatment. Medical necessity may be supported when a drug is administered for an oncologic indication in accordance with FDA labeling or when the use has an NCCN Category 1, 2A, or 2B recommendation. The proposed dose, frequency, and duration should also be consistent with at least one authoritative source, such as FDA labeling, NCCN guidance or compendia, MCG, DrugDex, professional society guidelines, or CMS coverage policy.

    Key Terms and Reference Standards

    Authoritative source
    DefinitionA nationally recognized reference or standard supporting drug efficacy, dosing, frequency, duration, or medical necessity.
    ExamplesFDA labeling, MCG care guidelines, DrugDex at level IIa or higher, NCCN Guidelines or Compendia at level IIb or higher, professional society guidelines, peer-reviewed literature, and CMS coverage policy.
    Policy expectationThe proposed drug dose, frequency, and duration must be consistent with recommendations in at least one authoritative source.
    NCCN Guidelines or NCCN Compendium
    DefinitionThe National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology or its derivative NCCN Drugs & Biologics Compendium.
    NCCN GuidelinesEvidence-based recommendations for the diagnosis and treatment of cancer and cancer care supportive therapies.
    Policy Summary
    PayerHealthSpring
    PolicyOncology and Supportive Care Medications
    Policy CodePolicy RX502.061
    Change TypeTable 1 medication and code list updated
    Effective DateOctober 20, 2026
    Next Review DateN/A
    Key ActionReview the Medical Policy and the member’s benefit contract or Summary Plan Description when making coverage determinations.
    SourceLink
    On This Page
    Oncology Medication Medical NecessityOncology and Supportive-Care Medication CodesCoverage Review and Use RequirementsPolicy BackgroundKey Terms and Reference Standards
    Use in this policyNCCN Guidelines and Compendia are nationally recognized references supporting drug efficacy, dosing, frequency, duration, or medical necessity.
    FDA approval
    DefinitionFDA approval is the authorization to market a new drug or biologic for a specific indication after review by the Food and Drug Administration.
    SubmissionThe pharmaceutical company submits a New Drug Application or Biologic Licensing Application to request marketing approval in the United States.
    Supporting informationThe submission includes animal and human testing data and analysis, information about the drug’s behavior in the body, and manufacturing information; FDA reviewers evaluate evidence of safety and effectiveness for the proposed use.
    Off-label or unlabeled drug use
    DefinitionUse of an FDA-approved drug for an indication, treatment regimen, or patient population not included in the approved labeling.
    IndicationUse for a disease or condition other than those specifically included in the FDA-approved labeling.
    ContextMany off-label uses are effective, well-documented in the literature, and widely used.
    Unapproved or unlabeled use
    DefinitionDrug use for which the FDA has not been asked for approval.
    Range of useThese uses range from completely unstudied to thoroughly investigated.
    DistinctionApproved uses have been shown to be safe and effective by the FDA after review of adequate and controlled clinical trials documenting their uses.
    NCCN Category 1
    EvidenceBased upon high-level evidence.
    ConsensusThere is uniform NCCN consensus that the intervention is appropriate.
    Panel standardUniform NCCN consensus requires a majority NCCN Panel vote of at least 85%.
    NCCN Category 2A
    EvidenceBased upon lower-level evidence.
    ConsensusThere is uniform NCCN consensus that the intervention is appropriate.
    Panel standardUniform NCCN consensus requires a majority NCCN Panel vote of at least 85%.
    NCCN Category 2B
    EvidenceBased upon lower-level evidence.
    ConsensusThere is NCCN consensus that the intervention is appropriate.
    Panel standardNCCN consensus requires a Panel vote of at least 50% but less than 85%.
    NCCN Category 3
    EvidenceBased upon any level of evidence.
    ConsensusThere is major NCCN disagreement that the intervention is appropriate.
    Panel standardWhere there is strong Panel disagreement, NCCN requires a Panel vote of at least 25% to include and designate a recommendation as Category 3.
    NCCN Drugs & Biologics Compendium
    DefinitionA compendium containing FDA-approved cancer and cancer supportive-care indications and recommended non-FDA-approved uses.
    FDA-approved usesIncludes FDA-approved indications for cancer and cancer supportive care.
    NCCN-supported usesIncludes recommended non-FDA-approved uses based on recommendations contained within the NCCN Guidelines.
    FDA-approved indication
    DefinitionAn indication for which the FDA has authorized the medication based on its review of clinical data.
    Marketing authorityOnce approved, the pharmaceutical company may market the drug based on the FDA-approved indications.
    Regulatory basisThe FDA is responsible for reviewing clinical data before approval of a new medication.
    Non-FDA-approved oncology indication
    DefinitionAn oncology medication use that is not FDA-approved but is supported by recommendations of an NCCN Panel.
    Where includedThe use is contained in the NCCN Guidelines and/or the NCCN Drugs & Biologics Compendium.
    Coverage contextOncology medications may be used for indications not approved by the FDA when supported by NCCN Panel recommendations and contained in these NCCN resources.